相似文献
1
Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.
Vaccine. 2007 Nov 23;25(48):8180-9. doi: 10.1016/j.vaccine.2007.09.038. Epub 2007 Oct 5.
2
Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.
Vaccine. 2007 Oct 16;25(42):7441-9. doi: 10.1016/j.vaccine.2007.08.016. Epub 2007 Aug 30.
3
Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept.
Vaccine. 2010 Jan 8;28(3):594-6. doi: 10.1016/j.vaccine.2009.10.015. Epub 2009 Oct 22.
4
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Virology. 1997 Dec 22;239(2):389-401. doi: 10.1006/viro.1997.8878.
5
The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.
Vaccine. 2008 Sep 15;26(39):4998-5003. doi: 10.1016/j.vaccine.2008.07.011. Epub 2008 Jul 24.
6
Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
J Virol. 2017 Sep 27;91(20). doi: 10.1128/JVI.01202-17. Print 2017 Oct 15.
7
Replicon particle vaccine protects swine against influenza.
Comp Immunol Microbiol Infect Dis. 2010 Dec;33(6):e99-e103. doi: 10.1016/j.cimid.2010.05.002. Epub 2010 Jun 17.
8
Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques.
Vaccine. 2011 Jan 29;29(5):931-40. doi: 10.1016/j.vaccine.2010.11.024. Epub 2010 Nov 25.
9
VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.
Vaccine. 2018 May 17;36(21):2937-2945. doi: 10.1016/j.vaccine.2018.04.048. Epub 2018 Apr 23.
10
Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine.
Vaccine. 2012 Mar 2;30(11):1944-50. doi: 10.1016/j.vaccine.2012.01.030. Epub 2012 Jan 23.
引用本文的文献
1
Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals.
Microbiol Spectr. 2023 Mar 1;11(2):e0485422. doi: 10.1128/spectrum.04854-22.
2
Expression and Immunogenicity of Recombinant African Swine Fever Virus Proteins Using the Semliki Forest Virus.
Front Vet Sci. 2022 May 9;9:870009. doi: 10.3389/fvets.2022.870009. eCollection 2022.
3
Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory.
PLoS One. 2021 Dec 2;16(12):e0259301. doi: 10.1371/journal.pone.0259301. eCollection 2021.
4
Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA.
Mol Ther Nucleic Acids. 2021 Jun 24;25:483-493. doi: 10.1016/j.omtn.2021.06.008. eCollection 2021 Sep 3.
5
An -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates.
Sci Transl Med. 2020 Aug 5;12(555). doi: 10.1126/scitranslmed.abc9396. Epub 2020 Jul 20.
6
Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance.
J Pharm Anal. 2020 Aug;10(4):291-312. doi: 10.1016/j.jpha.2020.01.002. Epub 2020 Jan 13.
7
Next-generation influenza vaccines: opportunities and challenges.
Nat Rev Drug Discov. 2020 Apr;19(4):239-252. doi: 10.1038/s41573-019-0056-x. Epub 2020 Feb 14.
8
Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs.
Vaccine. 2019 Mar 7;37(11):1533-1539. doi: 10.1016/j.vaccine.2018.12.071. Epub 2019 Feb 2.
9
Short- and long-term protective efficacy against clade 2.3.4.4 H5N2 highly pathogenic avian influenza virus following prime-boost vaccination in turkeys.
Vaccine. 2017 Oct 9;35(42):5637-5643. doi: 10.1016/j.vaccine.2017.08.059. Epub 2017 Sep 6.
10
The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.
Antiviral Res. 2015 May;117:75-98. doi: 10.1016/j.antiviral.2015.02.011. Epub 2015 Mar 5.
本文引用的文献
1
Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.
Clin Vaccine Immunol. 2007 Jun;14(6):748-55. doi: 10.1128/CVI.00037-07. Epub 2007 Apr 18.
2
Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
PLoS Med. 2007 Feb;4(2):e59. doi: 10.1371/journal.pmed.0040059.
3
Alphavirus replicon approach to promoterless analysis of IRES elements.
Virology. 2007 Apr 10;360(2):376-87. doi: 10.1016/j.virol.2006.10.049. Epub 2006 Dec 6.
4
General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2006 Dec 1;55(RR-15):1-48.
5
Mucosal and systemic adjuvant activity of alphavirus replicon particles.
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3722-7. doi: 10.1073/pnas.0600287103. Epub 2006 Feb 27.
6
Are we ready for pandemic influenza?
Science. 2003 Nov 28;302(5650):1519-22. doi: 10.1126/science.1090350.
7
Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.
Vaccine. 2003 Feb 14;21(9-10):946-9. doi: 10.1016/s0264-410x(02)00545-5.
8
Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge.
Vaccine. 2001 Oct 12;20(1-2):218-25. doi: 10.1016/s0264-410x(01)00268-7.
9
Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.
Vaccine. 1999 Dec 10;18(9-10):899-906. doi: 10.1016/s0264-410x(99)00334-5.
10
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Virology. 1997 Dec 22;239(2):389-401. doi: 10.1006/viro.1997.8878.
Zotero 插件